Vikram Karnani is executive vice president, and president, Global Commercial Operations and Medical Affairs, responsible for leading Amgen’s Rare Disease business. Karnani joined the company in 2023 through Amgen’s acquisition of Horizon Therapeutics, a leading rare disease company. Karnani joined Horizon in 2014, holding numerous leadership positions spanning nearly every aspect of Horizon’s business. For example, he led Horizon’s international commercial organization for several years, working to make the company’s medicines available to patients outside the U.S.

Before joining Horizon, Karnani was with Fresenius Kabi, a company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, where he served as vice president of the therapeutics and cell therapy business.

Karnani received a Master of Business Administration from the Kellogg School of Management at Northwestern University, a master's degree in electrical engineering from Case Western Reserve University, and a bachelor's degree in electrical engineering from University of Bombay, India.